Ground News

institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

cancernetwork.com image

News from cancernetwork.com

See all of cancernetwork.com news coverage in one place. Discover how cancernetwork.com’s media bias informs their coverage and compare with thousands of other news outlets.

Ground News has come across 673 headlines reported on by cancernetwork.com during the past 3 months.

Ground News rates cancernetwork.com’s media bias as unknown. . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is cancernetwork.com credible or reliable? Our Factuality score answers both of those questions. When it comes to cancernetwork.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about cancernetwork.com

Where is cancernetwork.com located?cancernetwork.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top cancernetwork.com News

New Drug Combination Shows High Remission Rates in Acute Myeloid Leukemia

New Drug Combination Shows High Remission Rates in Acute Myeloid Leukemia

100% Center coverage: 3 sources

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an early-phase clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and 11 other sites nationwide.See the Story

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Merck & Co (NYSE:MRK)

Cancer · United States

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Merck & Co (NYSE:MRK)

100% Center coverage: 2 sources

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (combined positive score of at least 1), as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent…See the Story

Next-Generation TKI Approved for Advanced ROS1-Positive Lung Cancer

Pharma · United States

Next-Generation TKI Approved for Advanced ROS1-Positive Lung Cancer

100% Center coverage: 2 sources

(MedPage Today) -- The FDA approved taletrectinib (Ibtrozi) -- a next-generation oral ROS1 tyrosine kinase inhibitor (TKI) -- for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)...See the Story

Sasanlimab Plus BCG in BCG-Naive, High-Risk Non-Muscle Invasive Bladder Cancer: the Randomized Phase 3 CREST Trial

100% Center coverage: 2 sources

Bacillus Calmette–Guérin (BCG) induction and maintenance (I+M) after transurethral resection of bladder tumor is standard of care (SOC) in high-risk non-muscle invasive bladder cancer (NMIBC). However, disease recurrence/progression occurs in approximately 40% of patients at 2 years, with unfavorable prognosis. Limited bladder-sparing therapeutic options exist, and no improvements to response durability have been observed in decades. CREST is a …United States · United States See the Story

Colorectal Cancer Linked With Adverse Sexual Health Outcomes

100% Right coverage: 1 sources

Study findings highlight an unexpected outcome in colorectal cancer survivors: Significant sexual health issues.Cancer · Portugal See the Story

Serplulimab Yields Sustained OS/PFS Benefits in Extensive-Stage SCLC

Biomarker analyses indicate the predictive potential of a 15-protein signature related to the efficacy of serplulimab plus chemotherapy in ES-SCLC.Read Article

No Deaths Observed Related to Nivolumab in Resected Gastric Cancers

Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.Read Article

Similar Splenic, Symptom Responses Are Reported With Ruxolitinib Combos in Myelofibrosis With Anemia

Results of a post hoc analysis found spleen and symptom response rates to be comparable with ESAs or danazol in combination with ruxolitinib for patients with myelofibrosis who have anemia.Read Article

Cyclosporin/Cyclophosphamide Is a Potential New SOC in GVHD Management

Treatment with cyclosporin/cyclophosphamide following allogeneic stem cell transplant had improved efficacy vs cyclosporin/methotrexate in patients with high-risk hematologic cancers.Read Article

Boosting CAR T cell survival to improve solid tumor therapy

100% Center coverage: 2 sources

Chimeric Antigen Receptor (CAR)-T cells are a promising cancer therapy that are made from the patient's own T cells, which are reprogrammed to fight their cancer. One of the limitations of CAR-T cell therapy is the ability of these cells to survive long enough to target the entire tumor.Cancer See the Story

Nadunolimab Earns FDA Fast-Track Designation in Metastatic PDAC

The FDA decision follows phase 2 CANFOUR trial data showing a 2-year survival rate of 35% in IL1RAP-high metastatic pancreatic ductal adenocarcinoma.United States · United States See the Story

Breaking News Topics Related to cancernetwork.com